INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41m ago
HOUSE PTR1m ago
SEC 13F54s ago
ROBINHOOD CHAIN45s ago
Public company

ANIPANI PHARMACEUTICALS INC

CIK 0001023024

EDGAR filingsOpen in network
Disclosed transactions37
Buys / sells0 / 25
Max Insider Score39
Connections12with evidence

ANIP · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
CP
Carey Stephen P.SVP & CFO
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$208K
2,850 sh
Oct 29, 2026Oct 30, 2026
traded Oct 29, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Gosebruch Henry ODirector · Aug 27, 2026
  • ← Insider ofevidence
    Carey Stephen P.SVP & CFO · Jun 30, 2026
  • ← Insider ofevidence
    Thoma JeanneDirector · Jun 10, 2026
17
LN
Lalwani NikhilDirector, PRESIDENT & CEO
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL
$388K
5,400 sh
Oct 15, 2026
Oct 16, 2026
traded Oct 15, 2026
+1d
SEC FORM 4

Evidence

8
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$37K
500 sh
Oct 13, 2026Oct 13, 2026
traded Oct 13, 2026
+0dSEC FORM 4

Evidence

14
CP
Carey Stephen P.SVP & CFO
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$208K
2,850 sh
Sep 29, 2026Sep 30, 2026
traded Sep 29, 2026
+1dSEC FORM 4

Evidence

22
LN
Lalwani NikhilDirector, PRESIDENT & CEO
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$383K
5,400 sh
Sep 15, 2026Sep 16, 2026
traded Sep 15, 2026
+1dSEC FORM 4

Evidence

8
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$35K
500 sh
Sep 14, 2026Sep 14, 2026
traded Sep 14, 2026
+0dSEC FORM 4

Evidence

18
TJ
Thoma JeanneDirector
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$72K
1,000 sh
Sep 11, 2026Sep 14, 2026
traded Sep 11, 2026
+3dSEC FORM 4

Evidence

19
GO
Gosebruch Henry ODirector
ANIPANI PHARMACEUTICALS INC
Grant or award
A—
6,662 sh
Aug 19, 2026Aug 27, 2026
traded Aug 19, 2026
+8dSEC FORM 4

Evidence

16
LN
Lalwani NikhilDirector, PRESIDENT & CEO
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$401K
5,400 sh
Aug 25, 2026Aug 26, 2026
traded Aug 25, 2026
+1dSEC FORM 4

Evidence

8
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$38K
500 sh
Aug 13, 2026Aug 13, 2026
traded Aug 13, 2026
+0dSEC FORM 4

Evidence

29
GO
Gutwerg OriSVP, GENERICS
ANIPANI PHARMACEUTICALS INC
Open-market sale
SELL$243K
3,162 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

8
CP
Carey Stephen P.SVP & CFO
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$240K
2,850 sh
Jun 29, 2026Jun 30, 2026
traded Jun 29, 2026
+1dSEC FORM 4

Evidence

0
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$41K
500 sh
Jun 12, 2026Jun 15, 2026
traded Jun 12, 2026
+3dSEC FORM 4

Evidence

23
TJ
Thoma JeanneDirector
ANIPANI PHARMACEUTICALS INC
Grant or award
A—
4,357 sh
May 21, 2026Jun 10, 2026
traded May 21, 2026
+20dSEC FORM 4

Evidence

31
LJ
Leonard Matthew JDirector
ANIPANI PHARMACEUTICALS INC
Grant or award
A—
4,357 sh
May 21, 2026Jun 10, 2026
traded May 21, 2026
+20dSEC FORM 4

Evidence

1
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$39K
500 sh
May 13, 2026May 13, 2026
traded May 13, 2026
+0dSEC FORM 4

Evidence

1
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$39K
500 sh
Apr 13, 2026Apr 13, 2026
traded Apr 13, 2026
+0dSEC FORM 4

Evidence

6
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$36K
500 sh
Mar 13, 2026Mar 13, 2026
traded Mar 13, 2026
+0dSEC FORM 4

Evidence

16
DK
Davis KristaSVP, CHIEF HR OFFICER
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$377K
5,087 sh
Mar 9, 2026Mar 10, 2026
traded Mar 9, 2026
+1dSEC FORM 4

Evidence

9
DK
Davis KristaSVP, CHIEF HR OFFICER
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$111K
1,485 sh
Mar 6, 2026Mar 10, 2026
traded Mar 6, 2026
+4dSEC FORM 4

Evidence

4
DK
Davis KristaSVP, CHIEF HR OFFICER
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$135K
1,730 sh
Feb 20, 2026Feb 23, 2026
traded Feb 20, 2026
+3dSEC FORM 4

Evidence

4
DK
Davis KristaSVP, CHIEF HR OFFICER
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$162K
2,084 sh
Feb 19, 2026Feb 23, 2026
traded Feb 19, 2026
+4dSEC FORM 4

Evidence

8
DK
Davis KristaSVP, CHIEF HR OFFICER
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$100K
1,290 sh
Feb 14, 2026Feb 17, 2026
traded Feb 14, 2026
+3dSEC FORM 4

Evidence

14
DK
Davis KristaSVP, CHIEF HR OFFICER
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$91K
1,180 sh
Feb 12, 2026Feb 17, 2026
traded Feb 12, 2026
+5dSEC FORM 4

Evidence

12
DK
Davis KristaSVP, CHIEF HR OFFICER
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$230K
3,017 sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

22
LN
Lalwani NikhilDirector, PRESIDENT & CEO
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$2.34M
30.7K sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

15
MC
Mutz ChristopherHEAD OF RARE DISEASE
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$347K
4,546 sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

19
GO
Gutwerg OriSVP, GENERICS
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$325K
4,267 sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

15
GC
Gassert ChadSVP - CORP. DEV. & STRATEGY
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$326K
4,269 sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

8
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$230K
3,011 sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

12
SM
Shanmugam MuthusamyDirector, HEAD OF R&D, COO-NOVITIUM OPS
ANIPANI PHARMACEUTICALS INC
Tax withholding
F$221K
2,898 sh
Feb 11, 2026Feb 13, 2026
traded Feb 11, 2026
+2dSEC FORM 4

Evidence

1
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$42K
500 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

13
DK
Davis KristaSVP, CHIEF HR OFFICER
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$134K
1,622 sh
Dec 18, 2025Dec 19, 2025
traded Dec 18, 2025
+1dSEC FORM 4

Evidence

6
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$33K
400 sh
Dec 12, 2025Dec 12, 2025
traded Dec 12, 2025
+0dSEC FORM 4

Evidence

39
GC
Gassert ChadSVP - CORP. DEV. & STRATEGY
ANIPANI PHARMACEUTICALS INC
Open-market sale
SELL$1.30M
14.6K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC FORM 4

Evidence

22
GC
Gassert ChadSVP - CORP. DEV. & STRATEGY
ANIPANI PHARMACEUTICALS INC
Open-market sale
SELL$8,272
94 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC FORM 4

Evidence

10
CM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
ANIPANI PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$35K
400 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC FORM 4

Evidence

← Insider ofevidence
Leonard Matthew J
Director · Jun 10, 2026
  • ← Insider ofevidence
    Shanmugam MuthusamyDirector, HEAD OF R&D, COO-NOVITIUM OPS · Feb 13, 2026
  • ← Insider ofevidence
    Lalwani NikhilDirector, PRESIDENT & CEO · Feb 13, 2026
  • ← Insider ofevidence
    Mutz ChristopherHEAD OF RARE DISEASE · Feb 13, 2026
  • ← Insider ofevidence
    Gutwerg OriSVP, GENERICS · Feb 13, 2026
  • ← Insider ofevidence
    Davis KristaSVP, CHIEF HR OFFICER · Dec 19, 2025
  • ← Insider ofevidence
    Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · Nov 14, 2025
  • ← Insider ofevidence
    Gassert ChadSVP - CORP. DEV. & STRATEGY · Nov 14, 2025